August 8, 2018 04:37 PM EDT
Pharma

Sarep­ta all-in on gene ther­a­py pipeline, adding 3 CNS treat­ments in $30M Lac­er­ta deal

John Carroll

Editor & Founder

Sarep­ta’s lead gene ther­a­py $SRPT may be on clin­i­cal hold, but the brash Duchenne mus­cu­lar dy­s­tro­phy com­pa­ny is con­tin­u­ing its deep dive in­to the field …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

A service from the Financial Times